Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Evaluation of the Anti-septic Effect of a Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) During Experimental Gingivitis

6 lipca 2026 zaktualizowane przez: University of Bern

Protocol Title Evaluation of the Anti-septic Effect of a Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) Compared to Placebo, During Experimental Gingivitis

Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.

Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.

Przegląd badań

Status

Rejestracja na zaproszenie

Szczegółowy opis

Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.

Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.

Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.

Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation.

During the study period, participants will be asked to rinse with the mouthrinse sample or the placebo for 60 seconds twice daily, under video supervision (participants send in video recordings of their rinsing to control adherence to the protocol). A dental assistant, unaware of the study's purpose, will distribute the samples. The containers will be unlabeled, ensuring that both the participants and examiners are blinded to group allocation.

At Days 0, 7, 14 and 21 of the experiment, clinical examinations will be performed from central incisors to the second molars in each participant. The Discoloration Index (DI17) will be recorded at three aspects on each tooth (mesial, buccal and distal). The criteria for the Discoloration Index (DI) are indicated in Table 1. Plaque and Gingivitis Indices will be assessed at 4 aspects of each tooth (mesial, buccal, distal and lingual) using the criteria of the Plaque Index system (PlI) (Silness & Löe 1964) and the Gingival Index System (GI) (Löe & Silness 1963) 16, 18. At each visit, the parameters will be assessed by the same examiner, who will be masked by the allocation of the test and control to avoid examiner bias and calibration bias.

Upon completion of the experimental period, mechanical daily plaque control measures will be re-instated and the participants will be re-examined after 3 weeks to ensure their periodontal health. Following the experimental period, another professional cleansing will be performed to remove plaque and possible stain on the teeth. At day 35 the participants will be checked again.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

33

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Canton of Bern
      • Bern, Canton of Bern, Szwajcaria, 3010
        • Department of Periodontology, University of Bern

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły

Akceptuje zdrowych ochotników

Tak

Opis

Inclusion Criteria:

  • systemically healthy,
  • non-smoker, former smokers > 5 years,
  • at least 24 teeth,
  • clinical diagnosis of periodontal health or gingivitis as determined by pocket probing depth not exceeding 4 mm with concomitant bleeding on probing.

Exclusion Criteria:

  • clinically visible carious lesions,
  • systemic antibiotics within 3 months prior to enrolment
  • vulnerable persons

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Placebo Group
Group P rinses twice daily with 10 ml of a placebo (pure water with flavored additive) solution
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero. The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
Eksperymentalny: Group T1
Group T1 rinses twice daily with 10 ml of 0.12% chlorhexidine solution with ADS (Anti-Discoloration System) solution (Curasept ADS 212)
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero. The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
Eksperymentalny: Group T2
Group T2 rinses twice daily with 10 ml of 0.12% chlorhexidine with HA (Hyaluronic Acid)
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero. The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
Ramy czasowe: at day 21
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
at day 21

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
Ramy czasowe: at day 0, 7, 14, and 35
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
at day 0, 7, 14, and 35
Plaque accumulation, assessed by the Plaque Index Silness and Löe 1994
Ramy czasowe: at day 0, 7, 14, 21 and 35
The index is a scoring system assessing the plaque at 4 surfaces of the teeth, starting at 0 for no plaque visible to 3 with an abundance of plaque creating a thick layer that fills the interdental space.
at day 0, 7, 14, 21 and 35
Staining assessed by the Discoloration index
Ramy czasowe: at day 0, 7, 14, 21 and 35
The discoloration is an index from 0: no discoloration to 3: Heavy brown and black discoloration over the entire extent of the tooth surface, black discoloration predominantly on the interproximal surfaces
at day 0, 7, 14, 21 and 35
Oral scan
Ramy czasowe: at day 0, 21 and 35
Oral scans will be performed to study changes in gingival texture, volume and colour or other changes
at day 0, 21 and 35
Microbiological changes
Ramy czasowe: at day 0, 21 and 35
Changes in 8 periodontopathogens will be assessed by Multiplex PCR
at day 0, 21 and 35
Characterisation of host- and microbiome-derived metabolites
Ramy czasowe: at day 0, 21 and 35
From selective participants, host-derived metabolites will be assessed by untargeted liquid chromatography-mass spectrometry (LC-MS) to study molecular changes throughout disease progression and possible relationships with other generated datasets.
at day 0, 21 and 35

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

8 lipca 2026

Zakończenie podstawowe (Szacowany)

7 września 2026

Ukończenie studiów (Szacowany)

7 sierpnia 2027

Daty rejestracji na studia

Pierwszy przesłany

6 lipca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

6 lipca 2026

Pierwszy wysłany (Rzeczywisty)

10 lipca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

10 lipca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

6 lipca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • V4ExpAugGingivitis

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Experimental gingivitis model

3
Subskrybuj